Gender influences the class III and V b-tubulin ability to predict poor outcome in colorectal cancer

Clinical Cancer Research

Volumn 18, Issue 10, 2012, Pages 2964-2975

  Mariani, Marisa ^a,b   Zannoni, Gian Franco ^c   Sioletic, Stefano ^c   Sieber, Steven ^a   Martino, Candice ^a   Martinelli, Enrica ^b   Coco, Claudio ^c   Scambia, Giovanni ^b   Shahabi, Shohreh ^a   Ferlini, Cristiano ^a,b  

^a DANBURY HOSPITAL   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA TUBULIN; BETA TUBULIN 3; BETA TUBULIN 6; FIRTECAN; OXALIPLATIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER MORTALITY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; FEMALE; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPIC VARIATION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; ORGANOPLATINUM COMPOUNDS; RECEPTORS, ANDROGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SEX CHARACTERISTICS; STEROID 17-ALPHA-HYDROXYLASE; TREATMENT OUTCOME; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84861168754     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2318     Document Type: Article

References (29)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008. Int J Cancer 2010;127:2893-917.
2. Waldner MJ, Neurath MF. The molecular therapy of colorectal cancer. Mol Aspects Med 2010;31:171-8.
3. Weinmann M, Belka C, Plasswilm L. Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours. Onkologie 2004;27:83-90. (Pubitemid 38338499) (Pubitemid 38338499)
4. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 1997;36:3554-62. (Pubitemid 27143509) (Pubitemid 27143509)
5. Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L, et al. Hypoxia induces class III beta-tubulin gene expression by HIF- 1alpha binding to its 3′ flanking region. Gene 2008;409:100-8.
6. Raspaglio G, De Maria I, Filippetti F, Martinelli E, Zannoni GF, Prislei S, et al. HuR regulates beta-tubulin isotype expression in ovarian cancer. Cancer Res 2010;70:5891-900.
7. McCarroll JA, Gan PP, Liu M, Kavallaris M. BetaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res 2010;70:4995-5003.
8. Cicchillitti L, Penci R, Di Michele M, Filippetti F, Rotilio D, Donati MB, et al. Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin. Mol Cancer Ther 2008;7:2070-9.
9. Joe PA, Banerjee A, Luduena RF. The roles of cys124 and ser239 in the functional properties of human betaIII tubulin. Cell Motil Cytoskeleton 2008;65:476-86. (Pubitemid 351794103) (Pubitemid 351794103)
10. Verdier-Pinard P, Shahabi S, Wang F, Burd B, Xiao H, Goldberg GL, et al. Detection of human betaV-tubulin expression in epithelial cancer cell lines by tubulin proteomics. Biochemistry 2005;44:15858-70. (Pubitemid 41746916) (Pubitemid 41746916)
11. Mozzetti S, Iantomasi R, De Maria I, Prislei S, Mariani M, Camperchioli A, et al. Molecular mechanisms of patupilone resistance. Cancer Res 2008;68:10197-204.
12. Prislei S, Mozzetti S, Filippetti F, De Donato M, Raspaglio G, Cicchillitti L, et al. From plasma membrane to cytoskeleton: a novel function for semaphorin 6A. Mol Cancer Ther 2008;7:233-41.
13. De Donato M, Mariani M, Petrella L, Martinelli E, Zannoni GF, Vellone V, et al. Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 2012;227:1034-41.
14. Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology 2010;78:237-48.
15. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12:2774-9.
16. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16-22.
17. Zmuda JM, Cauley JA, Kuller LH, Ferrell RE. A common promotor variant in the cytochrome P450c17alpha (CYP17) gene is associated with bioavailability testosterone levels and bone size in men. J Bone Miner Res 2001;16:911-7. (Pubitemid 32332301) (Pubitemid 32332301)
18. Seve P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receivingtubulin-bindingagents? LancetOncol 2008;9:168-75. (Pubitemid 351150128) (Pubitemid 351150128)
19. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11:298-305. (Pubitemid 40075808) (Pubitemid 40075808)
20. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, et al. Expression of Tubb3, a beta-tubulin isotype, is regulated by androgens in mouse and rat sertoli cells. Biol Reprod 2011;85:934-45.
21. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005; 96:1241-6. (Pubitemid 41743917) (Pubitemid 41743917)
22. Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000;60:5710-3.
23. Severi G, Hayes VM, Tesoriero AA, Southey MC, Hoang HN, Padilla EJ, et al. The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. BJU Int 2008;101:492-6. (Pubitemid 351187644) (Pubitemid 351187644)
24. Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 2007;16:2237-46. (Pubitemid 351196355)
25. Berg SJ, Wynne-Edwards KE. Changes in testosterone, cortisol, and estradiol levels in men becoming fathers. Mayo Clin Proc 2001;76: 582-92. (Pubitemid 32525133)
26. Vidovic M, Hisheh S, Schmitt LH. Cortisol and testosterone levels on a weekend and a work day in three mountain villages in the Selska Valley of northwest Slovenia. Ann Hum Biol 2007;34:26-33.
27. Yousefi M, Karmaus W, Mudd LM, Landgraf JR, Mikucki D, Haan PS, et al. Expression of CYP19 and CYP17 is associated with leg length, weight, and BMI. Obesity (Silver Spring) 2011;19:436-41.
28. Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 2010;28:4086-93.
29. Moon RC, Fricks CM. Influence of gonadal hormones and age on 1,2-dimethylhydrazine-induced colon carcinogenesis. Cancer 1977;40: 2502-8. (Pubitemid 8237753) (Pubitemid 8237753)